Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global Gene Therapy for Age-related Macular Degeneration market was valued at USD 175 million in 2024 and is projected to reach USD 480 million by 2031, exhibiting a CAGR of 15.5% during the forecast period. This growth is primarily driven by the rising prevalence of AMD, particularly in aging populations, and increasing investments in gene therapy research.
Gene therapy for AMD involves delivering functional genes to retinal cells to correct genetic defects or provide therapeutic proteins. These therapies target both dry AMD (accounting for 85-90% of cases) and wet AMD, with approaches including subretinal and intravitreal delivery methods. The therapy aims to provide long-term treatment benefits compared to current anti-VEGF injections that require frequent administration.
Key growth drivers include accelerating clinical trial activity, with over 15 gene therapy candidates currently in clinical development for AMD. Major players like REGENXBIO and AGTC are advancing innovative vectors such as AAV-based delivery systems. Additionally, favorable regulatory pathways for orphan drug designations and the potential for one-time treatment solutions are catalyzing market expansion. However, challenges remain in achieving safe, targeted delivery and demonstrating long-term efficacy.
Increasing Prevalence of Age-related Macular Degeneration
The global burden of age-related macular degeneration (AMD) is growing, with over 196 million people affected worldwide. Gene therapy offers a potential one-time treatment solution for this progressive eye disease, driving significant R&D investment.
Advancements in Viral Vector Technologies
Recent breakthroughs in AAV vector design have improved retinal targeting efficiency and safety profiles. The first FDA-approved retinal gene therapy (Luxturna) demonstrated proof-of-concept, establishing regulatory pathways for AMD treatments.
Over 45 gene therapy clinical trials are currently targeting AMD, with several in Phase 3 development
Growing physician acceptance of genetic medicines and increasing patient awareness are creating a receptive market environment for these advanced therapies.
MARKET CHALLENGES
High Development Costs and Complex Manufacturing
Gene therapies for AMD face manufacturing challenges due to the need for precise retinal delivery systems and strict quality control standards. The average development cost exceeds $1 billion per product.
Other Challenges
Regulatory Hurdles
The long-term safety profile of retinal gene therapies requires extensive monitoring, with the FDA mandating 15-year follow-up studies for approved products.
Patient Access Barriers
Current reimbursement models struggle with one-time high-cost therapies, with pricing expectations exceeding $500,000 per treatment.
Limited Target Patient Population
While AMD affects millions, only specific genetic subtypes (approximately 15-20% of cases) are currently addressable with gene therapy approaches. This restricts the immediate addressable market for these treatments.
Expansion into Earlier Disease Stages
Current trials are exploring gene therapy for dry AMD before geographic atrophy develops, potentially increasing the treatable population by 300%. Combination therapies with anti-VEGF treatments also present significant opportunities.
Emerging Delivery Technologies
Novel subretinal and suprachoroidal delivery devices in development could reduce procedural complexity and expand the pool of treatable patients beyond specialized centers.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Subretinal gene therapy dominates due to its precision in targeting retinal cells, while intravitreal injections face challenges with gene vector distribution. The former shows better potential for long-term therapeutic effects as it enables direct RPE cell access crucial for AMD treatment. |
| By Application |
|
Monotherapy approaches are gaining traction for their simplified treatment protocols, though combination therapies show promise for addressing complex AMD pathophysiology. The industry sees increasing R&D focus on gene therapies that can replace traditional anti-VEGF injections entirely. |
| By End User |
|
Specialty Clinics are emerging as preferred centers for gene therapy administration due to their specialized retinal expertise. However, hospitals maintain significant volume for complex cases, while research institutes drive pipeline innovation through clinical trials of next-generation therapies. |
| By Target AMD Type |
|
Wet AMD currently attracts more gene therapy development due to well-understood VEGF pathways, though dry AMD therapies are receiving increased attention. Geographic atrophy treatments represent an urgent unmet need driving innovation in neuroprotective genes and complement inhibition approaches. |
| By Therapeutic Approach |
|
Gene Replacement strategies currently lead the market due to their ability to deliver functional copies of compromised genes. However, gene editing technologies like CRISPR are emerging for more precise interventions, while RNA-based silencing approaches show promise for modulating disease pathways with reduced immunogenicity risks. |
Gene Therapy Breakthroughs Transforming AMD Treatment Paradigms
REGENXBIO Inc. emerges as the dominant player in the gene therapy for AMD market, leveraging its proprietary NAV Technology Platform for ocular gene delivery. The company's RGX-314 candidate demonstrates promising results in late-stage clinical trials for wet AMD. With strategic collaborations with AbbVie and other pharmaceutical giants, REGENXBIO has established a robust pipeline targeting various retinal diseases. The market structure favors innovators with advanced delivery systems, as intravitreal and subretinal administration routes remain critical differentiators.
Second-generation players like Adverum Biotechnologies and Nightstar Therapeutics (acquired by Biogen) focus on optimizing vector design and dosing regimens. Smaller biotechs such as Applied Genetic Technologies Corporation (AGTC) and MeiraGTx specialize in precision therapies for specific AMD subtypes. Academic spin-offs and university research partnerships continue to introduce novel therapeutic approaches, though commercialization hurdles persist for these emerging entities.
List of Key Gene Therapy for AMD Companies ProfiledREGENXBIO Inc.
Nightstar Therapeutics (Biogen)
MeiraGTx Holdings
RetroSense Therapeutics (now Allergan)
Spark Therapeutics (Roche)
Gyroscope Therapeutics (Novartis)
Neurotech Pharmaceuticals
Ocugen Inc.
ReNeuron Group
Biogen Inc.
The global gene therapy market for Age-related Macular Degeneration (AMD) was valued at $XX million in 2024, with projections indicating a CAGR of X% through 2031. This growth is driven by increasing prevalence of AMD among aging populations and advancements in genetic engineering technologies. The market is currently dominated by North America and Europe, accounting for over 60% of total revenues, though Asia-Pacific regions are emerging as high-growth areas due to improving healthcare infrastructure.
Other TrendsDominance of Dry AMD Treatment Development
With dry AMD representing 80-90% of all cases, research efforts are heavily focused on developing gene therapies for this subtype. Key clinical trials target genetic factors contributing to retinal pigment epithelium degeneration, with several therapies in Phase II/III trials showing promising results in slowing disease progression.
Delivery Method InnovationThe market is segmented by delivery methods, with subretinal and intravitreal injections being the primary approaches. Recent developments in viral vector technologies (particularly AAV vectors) have improved targeting precision and reduced immune reactions, leading to better treatment outcomes. Combination therapies using gene augmentation with anti-VEGF agents are also gaining traction for wet AMD cases.
Competitive Landscape Evolution
Major players like REGENXBIO and AGTC are leading the space, with their therapies currently in advanced clinical stages. The competitive landscape is witnessing increased M&A activity as larger pharmaceutical companies seek to acquire promising gene therapy platforms. Investment in manufacturing capacity for viral vectors has become a key differentiator among competitors.
Regulatory and Reimbursement DevelopmentsRegulatory agencies are establishing specialized pathways for gene therapy approvals, with the FDA having granted several breakthrough therapy designations for AMD treatments. The market is seeing evolving reimbursement models to address the high upfront costs of gene therapies, with outcomes-based payment structures gaining consideration among payers.
Regional Analysis: Gene Therapy for Age-related Macular Degeneration MarketEurope
Europe represents the second largest market for AMD gene therapies, with strong government support for rare disease treatments. The EMA has shown willingness to approve innovative therapies, though pricing pressures exist in some countries. Germany and the UK lead in clinical adoption due to their specialized ophthalmology networks. European research consortia are collaborating on groundbreaking AMD gene therapy approaches. However, fragmented reimbursement systems across EU nations create market access challenges for new therapies.
Asia-Pacific
The Asia-Pacific region shows the fastest growth potential for AMD gene therapies, driven by increasing healthcare spending and aging populations. Japan leads in regulatory innovation with its Sakigake designation system for breakthrough therapies. China and Australia are emerging as important clinical trial locations. Cultural acceptance of emerging therapies varies across the region. Infrastructure limitations in some countries may slow initial adoption despite growing unmet medical needs.
South America
South America's AMD gene therapy market remains in early stages, constrained by limited healthcare budgets and infrastructure challenges. Brazil shows the most potential with its developing biotechnology sector. Regulatory pathways for advanced therapies are still evolving across the region. Private healthcare systems in major cities may drive initial adoption, while broader access will depend on pricing strategies and local manufacturing capabilities.
Middle East & Africa
The MEA region presents limited but growing opportunities in select high-income markets like UAE and Saudi Arabia. Specialized eye centers in these countries are beginning to explore gene therapy options. Most of the region still relies on traditional AMD treatments due to cost barriers. Local clinical trials are rare, with patients typically accessing new therapies through medical tourism to Western countries.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Gene Therapy for Age-related Macular Degeneration market was valued at USD 175 million in 2024 and is projected to reach USD 480 million by 2031.
Which key companies operate in Global Gene Therapy for Age-related Macular Degeneration Market?
-> Key players include REGENXBIO, AGTC, and RetroSense Therapeutics, among others.
-> Key growth drivers include rising prevalence of AMD in aging populations, increasing gene therapy research investments, and over 15 candidates in clinical development.
-> North America is a leading market, while Asia shows significant development potential.
-> Emerging trends include AAV-based delivery systems, one-time treatment solutions, and therapies targeting both dry and wet AMD.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates